eJHaem (Aug 2023)

SARS‐CoV‐2 infections in patients enrolled on the Children's Oncology Group standard‐risk B‐cell acute lymphoblastic leukemia trial, AALL1731

  • Caitlin W. Elgarten,
  • John A. Kairalla,
  • Joel C. Thompson,
  • Tamara P. Miller,
  • Cindy Wang,
  • Susan Conway,
  • Mignon L. Loh,
  • Elizabeth A. Raetz,
  • Sumit Gupta,
  • Rachel E. Rau,
  • Anne Angiolillo,
  • Karen R. Rabin,
  • Sarah Alexander

DOI
https://doi.org/10.1002/jha2.697
Journal volume & issue
Vol. 4, no. 3
pp. 745 – 750

Abstract

Read online

Abstract Hematologic malignancy is a risk factor for severe coronavirus disease 2019 (COVID‐19) in adults; however, data specific to children with leukemia are limited. High‐quality infectious adverse event data from the ongoing Children's Oncology Group (COG) standard‐risk B acute lymphoblastic leukemia/lymphoma (ALL/LLy) trial, AALL1731, were analyzed to provide a disease‐specific estimate of SARS‐CoV‐2 infection outcomes in pediatric ALL. Of 253 patients with reported infections, the majority (77.1%) were asymptomatic or mildly symptomatic (CTCAE grade 1/2) and there was a single COVID‐19‐related death. These data suggest SARS‐CoV‐2 infection does not confer substantial morbidity among young patients with B‐lymphoblastic leukemia/lymphoma (B‐ALL/LLy).

Keywords